ENFORTUMAB VEDOTIN EJFV 20/30 MG INJECTION
"PADCEV (enfortumab vedotin-ejfv) is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a fully human
anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3) conjugated to the small molecule microtubule
disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine-citrulline
(vc) linker (SGD-1006). Conjugation takes place on cysteine residues that comprise the interchain disulfide
bonds of the antibody to yield a product with a drug-to-antibody ratio of approximately 3.8:1. The molecular
weight is approximately 152 kDa. PADCEV (enfortumab vedotin-ejfv) for injection is provided as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials for intravenous use. PADCEV is supplied as a 20 mg per vial and a 30 mg per vial and requires reconstitution with Sterile Water for Injection,"
PADCEV (enfortumab vedotin-ejfv) Injection - 20 mg and 30 mg of enfortumab vedotin-ejfv as a lyophilized powder in a single-dose vial for reconstitution.
The recommended dose of PADCEV is 1.25 mg/kg (up to a maximum dose of 125 mg) given as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
PADCEV (enfortumab vedotin-ejfv) is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
